# Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

> **NCT05033054** · — · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 33 (actual)

## Conditions studied

- Kidney Disease, Chronic
- Diabetes

## Interventions

- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT05033054
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2025-01-02
- **Final completion:** 2025-02-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05033054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05033054, "Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05033054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*